TransCode Therapeutics Strengthens Scientific Leadership with Key Appointment and MSU Research Pact
Event summary
- TransCode Therapeutics appointed Dr. Anna Moore as Chair of its Scientific Advisory Board on April 27, 2026.
- The company signed a sponsored research agreement with Michigan State University to accelerate pipeline development.
- Research will evaluate lead candidate TTX-MC138 in combination with Seviprotimut-L and standard-of-care therapies.
The big picture
TransCode Therapeutics is fortifying its scientific foundation with the appointment of a key co-founder and a strategic research partnership, aiming to address significant unmet needs in advanced metastatic cancer treatment. The move underscores the growing emphasis on RNA-targeted therapies and immuno-oncology approaches in oncology.
What we're watching
- Clinical Development Pace
- How quickly Michigan State University's research can advance TTX-MC138 through clinical trials.
- Combination Therapy Potential
- Whether the evaluation of TTX-MC138 with Seviprotimut-L uncovers meaningful synergies for advanced cancers.
- Scientific Leadership Impact
- The extent to which Dr. Moore's strategic guidance can accelerate TransCode's RNA-based therapeutic pipeline.
Related topics